Growth Story Still Intact For Abbvie Inc (ABBV)

Abbvie Inc (ABBV) concluded trading on Wednesday at a closing price of $187.34, with 4.38 million shares of worth about $820.43 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.41% during that period and on June 04, 2025 the price saw a gain of about 0.05%. Currently the company’s common shares owned by public are about 1.77B shares, out of which, 1.76B shares are available for trading.

Stock saw a price change of 2.32% in past 5 days and over the past one month there was a price change of -4.45%. Year-to-date (YTD), ABBV shares are showing a performance of 5.42% which increased to 16.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $159.77 but also hit the highest price of $218.66 during that period. The average intraday trading volume for Abbvie Inc shares is 7.92 million. The stock is currently trading 1.27% above its 20-day simple moving average (SMA20), while that difference is up 0.13% for SMA50 and it goes to -0.92% lower than SMA200.

Abbvie Inc (NYSE: ABBV) currently have 1.77B outstanding shares and institutions hold larger chunk of about 74.13% of that.

The stock has a current market capitalization of $330.92B and its 3Y-monthly beta is at 0.49. PE ratio of stock for trailing 12 months is 79.88, while it has posted earnings per share of $2.35 in the same period. Its PEG reads 5.25 and has Quick Ratio of 0.64 while making debt-to-equity ratio of 49.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABBV, volatility over the week remained 0.18% while standing at 1.82% over the month.

Stock’s fiscal year EPS is expected to rise by 20.82% while it is estimated to increase by 14.45% in next year. EPS is likely to grow at an annualized rate of 15.22% for next 5-years, compared to annual growth of -14.67% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on May 14, 2025 offering a Neutral rating for the stock and assigned a target price of $205 to it. Coverage by Cantor Fitzgerald stated Abbvie Inc (ABBV) stock as an Overweight in their note to investors on April 22, 2025, suggesting a price target of $210 for the stock. On December 10, 2024, BofA Securities Resumed their recommendations, while on December 05, 2024, Daiwa Securities Downgrade their ratings for the stock with a price target of $180. Stock get an Outperform rating from Leerink Partners on November 22, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.